Developing high-level medical communication materials that create an IMPACT
High Park North, Toronto
Joined May 2019
- Tweets147
- Following98
- Followers48
- Likes184
Check out our latest podcast episode: CUTTING EDGE ADVANCES IN THE TREATMENT OF LUNG CANCER with Dr. Barbara Melosky: buzzsprout.com/266306/149193….
In honour of Earth Day, we wanted to share our new webpage dedicated to sustainability: impactmedicom.com/sustainabi…. At IMPACT Medicom, we take pride in our efforts towards sustainability, with a commitment to plant 50 trees per project sold. We have now planted over 1,000 trees!
Check out our latest podcast episode: BIOMARKERS IN UPPER GI CANCER with @DrCBrezden and Dr. Catherine Streutker: buzzsprout.com/266306/149126….
Our latest podcast episode is up: Immunotherapy for Kidney Transplant Patients with Skin Cancer with Dr. Evan Lipson: lnkd.in/gnt8mDjm.
Follow our podcast on Spotify at lnkd.in/g7UAaiXV.
Check out our latest video capsule where Dr. Mark Taylor discusses the surgical implications for the treatment of cutaneous Squamous Cell Carcinoma. youtu.be/uk5JEUjbkDE. #skincancer #surgeon
Check out our latest video capsule where @evanlipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant: lnkd.in/gpcaCJy9.
Updates from ASH 2023: Check out our congress summary on the latest updates in CLL. With @LymphomaDocDave and @v_banerji : impactmedicom.com/congress-s….
Check out our latest video capsule from
@ASH_hematology ASH 2023 - A Perspective on CLL with @v_banerji and @LymphomaDocDave: youtube.com/watch?v=EaBS7r7x…
Live from ASH: Our latest video capsule includes Dr. Rami Kotb @MyelomaCanada and @CancerCareMB and Dr. Donna Reece @pmcancercentre and @UofT discussing their study on Isa-CYBORD in RR Transplant Eligible MM. lnkd.in/gsYg7kBu. #multiplemyeloma
LIVE FROM @ASH_hematology, Dr. Jennifer Brown from @DanaFarberNews discusses updates to the ALPINE trial on zanubrutinib vs ibrutinib in CLL: buzzsprout.com/266306/141034…
At the @ASH_hematology meeting in San Diego. Exciting atmosphere, love these opportunities to learn about promising new treatments.
IMPACT Medicom retweeted
Du nouveau d'importance dans le cancer urothélial avancé! Des résultats dont le @chumontreal peut être fier d'avoir contribué.
Live from ESMO!! Check out our video capsule on first-line treatment strategies for the management of la/mUC with Dr. Thomas Powles @tompowles1 and a Canadian discussion with @NormandBlais , Dr. Srikala Sridhar, and Dr Bernie Eigle: impactmedicom.com/video-caps…. #bladdercancer
Live from ESMO!! Check out our video capsule on first-line treatment strategies for the management of la/mUC with Dr. Thomas Powles @tompowles1 and a Canadian discussion with @NormandBlais , Dr. Srikala Sridhar, and Dr Bernie Eigle: impactmedicom.com/video-caps…. #bladdercancer
IMPACT Medicom retweeted
♨️ - EV302. Simply amazing: OS was significantly prolonged with EV+P vs chemo, reducing the risk of death by 53% (median OS, 31.5 mo vs 16.1 mo, respectively). Can’t wait to witness this breakthrough live #ESMO23
We are celebrating 8 years in business with a new and improved website: impactmedicom.com. Come and check it out!
IMPACT Medicom retweeted
🔥off the press: ESMO Guidance for Reporting Oncology real-World evidence (GROW)
@Annals_Oncology
doi.org/10.1016/j.annonc.202…
👉RWD are gaining increasing interest to complement clinical trials
👉Here, we provide detailed recommendations for reporting RWE studies in oncology
@myESMO @OncoAlert
Our final podcast episode r on "First Line la/mUC Evolving Treatment Strategies" is up. This episode with @NormandBlais Dr. Srikala Sridhar, and Dr Terence Friedlander features a round table discussion on the treatment of 1L la/mUC. lnkd.in/gyqPUxb6. #bladdercancer
Our final video capsule of the Webinar on "First Line la/mUC Evolving Treatment Strategies" is up. With @NormandBlais , Dr. Srikala Sridhar, and Dr Terence Friedlander and features a round table discussion on the treatment of 1L la/mUC. youtube.com/watch?v=qOQ0_oqB…. #bladdercancer
IMPACT Medicom retweeted
More (impressive) data on the intracranial activity of T-DXd. Real-world cohort from Japan, including 104 patients with HER2+ MBC, of which 90 with active brain mets and 19 with LMD. Consistently with TUXEDO-1, IC-ORR was 63%, IC-PFS was 16 months. #bcsm nature.com/articles/s41523-0…
Our latest podcast episode is up!
This episode with Dr. Srikala Sridhar discusses a clinical case on the first-line treatment for la/mUC: buzzsprout.com/266306/136109…. #bladdercancer
